SeroScience Ltd.
Recent R&D and clinical experience with novel biopharmaceuticals,
controlled-release and targeted drug formulations have brought to light novel adverse effects,
including those afflicting the immune system.
Acute hypersensitivity reactions with the potential of severe,
life-threatening anaphylactoid shock represent a newly emerging toxicity of many state-of-art
drug candidates.
It has been discovered that the cause of many of these hypersensitivity reactions is activation
of the complement system.
The term "complement activation-related pseudoallergy" (CARPA) was created to describe
this type of hypersensitivity.
SeroScience Ltd. specializes in contract research and consultation to assist partners
in establishing the potential of their developmental product for CARPA and to develop products
that do not induce it.
The in vitro evaluations and in vivo assays provided by SeroScience Ltd. establish
the reactogenicity of a developmental product, which may serve as predictive markers for the risk
of non-Ig-E-mediated acute hypersensitivity.
